Compare BWMN & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BWMN | ENGN |
|---|---|---|
| Founded | 1995 | 1999 |
| Country | United States | Canada |
| Employees | N/A | 82 |
| Industry | Military/Government/Technical | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 620.2M | 647.1M |
| IPO Year | 2021 | N/A |
| Metric | BWMN | ENGN |
|---|---|---|
| Price | $31.73 | $8.01 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $45.50 | $21.08 |
| AVG Volume (30 Days) | 91.7K | ★ 245.0K |
| Earning Date | 05-05-2026 | 06-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 329.41 | N/A |
| EPS | ★ 0.73 | N/A |
| Revenue | ★ $490,017,000.00 | N/A |
| Revenue This Year | $14.93 | N/A |
| Revenue Next Year | $11.57 | N/A |
| P/E Ratio | $42.90 | ★ N/A |
| Revenue Growth | ★ 14.88 | N/A |
| 52 Week Low | $21.70 | $2.66 |
| 52 Week High | $45.83 | $12.25 |
| Indicator | BWMN | ENGN |
|---|---|---|
| Relative Strength Index (RSI) | 58.24 | 53.86 |
| Support Level | $30.48 | $7.83 |
| Resistance Level | $36.83 | $8.14 |
| Average True Range (ATR) | 1.00 | 0.55 |
| MACD | 0.15 | 0.15 |
| Stochastic Oscillator | 87.10 | 54.89 |
Bowman Consulting Group Ltd is a professional services firm delivering engineering solutions to customers who own, develop, and maintain the built environment. It provides planning, engineering, construction management, commissioning, environmental consulting, geospatial, survey, land procurement, and other technical services to customers operating in a diverse set of end markets. Its services include Civil & Site Engineering, Transportation Engineering, MEP Engineering, Commissioning & Energy Efficiency, Energy Services, Water/Wastewater, Fire Protection, Construction Management, Survey/Geospatial, Environmental Consulting, Structural Engineering, Land Procurement & Right-of-Way, Landscape and Architecture/Planning.
enGene Holdings Inc is a clinical-stage biotechnology company mainstreaming genetic medicine through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs, beginning with non-muscle invasive bladder cancer (NMIBC). The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.